Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Sequestered Antibiotics

Shuttling drugs away from their intended targets can sometimes transform them into good antimicrobials

by Celia Henry Arnaud
February 28, 2011 | A version of this story appeared in Volume 89, Issue 9

[+]Enlarge
Credit: J. Am. Chem. Soc.
Peptide-conjugated methotrexate (green) accumulates in the cytoplasm of bacteria (top) and the mitochondria (red) of human cells (bottom).
Credit: J. Am. Chem. Soc.
Peptide-conjugated methotrexate (green) accumulates in the cytoplasm of bacteria (top) and the mitochondria (red) of human cells (bottom).

Shuttling drugs away from their intended targets can transform compounds that might otherwise be too toxic for people into good antimicrobials, according to researchers at the University of Toronto. Shana O. Kelley and Mark P. Pereira attached a mitochondria-­targeting peptide to the cancer drug methotrexate and demonstrated the drug’s antimicrobial abilities (J. Am. Chem. Soc., DOI: 10.1021/ja110246u). The researchers show that the conjugate accumulates in mitochondria in human cells, where it can’t reach its enzyme target, but in the cytoplasm in bacteria. In cell culture, the conjugate killed a broad range of bacteria, including methicillin-resistant Staphylococcus aureus, a microbe resistant to most drugs. Kelley’s group is starting to study animals to see whether the drug retains its activity and reduced toxicity. The approach could be general for other drugs, provided they have a convenient “synthetic handle to tinker with,” Kelley says. The demonstration with methotrexate “opens the door to using similar strategies to revisit or repurpose old molecules that may have been discarded at early stages of antibiotic development,” says infectious disease expert Gerard D. Wright of McMaster University, in Hamilton, Ontario.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.